Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $10.80.

RGLS has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th.

Regulus Therapeutics Stock Up 0.7 %

NASDAQ:RGLS opened at $1.54 on Wednesday. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The company has a fifty day simple moving average of $1.53 and a two-hundred day simple moving average of $1.68. The company has a market cap of $100.87 million, a price-to-earnings ratio of -1.44 and a beta of 1.61.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts expect that Regulus Therapeutics will post -0.88 EPS for the current year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $26,000. SG Americas Securities LLC acquired a new position in Regulus Therapeutics in the third quarter valued at $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the third quarter worth about $46,000. Barclays PLC increased its position in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at about $136,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.